China Tracker - Details for China Pharmaceuticals (CFMI)

 China Pharmaceuticals
Shares Outstanding (MRQ): 75.24 mill
New Shares / Dilution (TTM): 19.24 mill34.35%
Cash (MRQ): 9.51 mill1,263.87%
Account Receivables (MRQ): 12.42 mill1,650.61%
Account Receivables (Q/Q): -0.25 mill-2.01%
Long-Term Debt (MRQ): NO DEBT
Revenue Growth (Q/Q): -12.64% 
Revenue Growth (Y/Y): 8.99% 
Net Income Growth (Q/Q): 80.88% 
Net Income Growth (Y/Y): -17.99%
EPS Growth (Y/Y): -38.96%
Net Margin (Q/Q): 33.9% (16.4%)17.50% 
Net Margin (Y/Y): 33.9% (45.1%)-11.20% 
EPS | P/E (2 MRQ Projection): $0.110.09
CFPS | P/CF (2 MRQ Projection): $0.160.06
Price/Sales (2 MRQ Projection): 0.02
Price/Book (MRQ): 0.02
Auditor: ACSB & Co.
 
 Forward Projections (Fiscal Year)
EPS | P/E (Estimates updated 2011-06-28): $0.120.08
 Basic Facts and History (show more)
Reporting Type: U.S. Company (10-K Filings) 
Going Public: Reverse Merger on 2010-02-12 

 Business Outlook

Fiscal 2010 continues to be a transitional year for China Pharmaceuticals, Inc. as we prepare for the introduction of new drugs, and pursue additional opportunities for both organic growth and potential strategic acquisitions. Our current outlook reflects only the drugs that we have in hand today and will be subject to update as we execute strategic initiatives to expand our market position and profitability in the future. Based on our performance to date, we continue to remain extremely optimistic regarding our future growth prospects and look forward to sharing further details with our shareholders as we proceed with our expansion plans.

(Source: Business Wire, 2010-08-30)

We believe that our strong cash position will provide us with significant flexibility to pursue continued organic growth. We are focused on continuing to expand our portfolio of high margin products that address major disease categories and on continuing to build sustainable growth in revenues and profits. Fiscal 2010 is expected to be a transitional year for China Pharmaceuticals as we prepare for the introduction of new drugs, and pursue additional opportunities for both organic growth and potential strategic acquisitions. Our current outlook reflects only the drugs that we have in hand today and will be subject to update as we execute strategic initiatives to expand our market position and profitability in the future. We remain very confident regarding our future growth prospects and look forward to sharing further details with our shareholders as our expansion plans reach a definitive stage.

(Source: Business Wire, 2010-04-20)

 Investor Presentations
2010-09-11 (Powerpoint)   DOWNLOAD (right click, save as)
CFMI
Healthcare & Drugs
SCORE
6
READ: Score Cards Explained
SAFETY/RISK SCORE
HIGH RISK
DETAILS: Safety/Risk Model for CFMI
Current Price:  $0.01
F10k Day (2010-04-12): -98.89%$0.90
2009 Close: -99.74%$3.78
2010 Close: -98.81%$0.84
2011 Close: -90.91%$0.11
High (2012-07-30): -92.86%$0.14
Low (2012-10-19): -66.67%$0.03
Exchange: PNK
Market Capitalization: 0.75 mill
Total Shares: 75.24 mill
Float: n/a
Avg Volume: n/a
Last Quarter: 2011-03-31
Revenue (MRQ): 7.69 mill
Net Income (MRQ): 2.61 mill
Op. Cash Flow (MRQ): 4.71 mill
all financial data provided without warranty